Effects of @entity413 -insulin- XXXX solution on myocardial salvage and left ventricular function after primary angioplasty.

@entity1 @entity1188 @entity972 @entity583 @entity413
OBJECTIVE: To evaluate the effects of @entity413 -insulin- @entity972 (GIK) therapy on @entity1188 size and left ventricular function when used as an adjuvant therapy to primary angioplasty. DESIGN: Prospective, randomized, double-blind, placebo-controlled study. SETTING: Cardiac intensive care unit at a university hospital. @entity1 : Thirty-seven @entity1 with @entity583 for whom primary angioplasty was indicated. INTERVENTIONS: Eligible @entity1 were randomized by a blinded pharmacist to GIK solution (30% @entity413 in water with insulin 50 U/L, and KCl 40 mM/L) vs. placebo at 1.5 mL/kg/hr for 24 hrs. MEASUREMENTS AND MAIN RESULTS: Tc 99m sestamibi myocardial scintigraphy was performed at admission and at 3 months. Primary end points were the changes in left ventricular ejection fraction (LVEF) and the size of salvaged myocardium. Baseline clinical characteristics were similar in both groups. At the 3-month follow-up, a significant overall decrease in @entity1188 size (37 +/- 16% vs. 12 +/- 10%, p <.005) and an increase in LVEF (34 +/- 13% vs. 49 +/- 9%, p =.005) were observed. @entity1 randomized to GIK solution experienced a significant increase in their LVEF at 3 months (39 +/- 12 to 51 +/- 13, p =.002). @entity1 who received placebo had no significant differences between baseline and 3-month measurements (44 +/- 13 vs. 49 +/- 14, p = NS). There was a trend toward an increase in myocardial salvage in the GIK group, which did not reach statistical significance. When @entity1 from both groups were compared directly, differences in LVEF improvement were no longer significant. CONCLUSIONS: GIK solution did not improve LVEF or decrease the @entity1188 size among @entity1 undergoing primary angioplasty.
